Ad
related to: alendronate and bisphosphonate benefits weight loss scientific evidence
Search results
Results from the WOW.Com Content Network
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [ 4 ] Use is often recommended together with vitamin D , calcium supplementation , and lifestyle changes.
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...
Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
Alendronate, a common bisphosphonate drug, has a three carbon length side chain for example. [17] Risedronate has heterocyclic structure containing nitrogen. Heterocyclic nitrogen containing bisphosphonates have revealed better results in terms of activity compared to earlier bisphosphonates with nitrogen bound to carbon chain. Studies on ...
Bisphosphonates are popular drugs for treatment of osteoporosis. [1] Clodronic acid is a bisphosphonate used as a drug to treat osteoporosis. In biochemistry and medicinal chemistry, phosphonate groups are used as stable bioisosteres for phosphate, such as in the antiviral nucleotide analog, Tenofovir, one of the cornerstones of anti-HIV therapy.
Tentative evidence does not support the use of bisphosphonates as a standard treatment for secondary osteoporosis in children. [168] Different bisphosphonates have not been directly compared, therefore it is unknown if one is better than another. [122] Fracture risk reduction is between 25 and 70% depending on the bone involved. [122]
Etidronic acid and other bisphosphonates may be appropriate therapies for selected patients but are less commonly used. In one study it was reported that people experienced side effects when taking bisphosphonates for six months, however the quality of evidence was low. [27] None of these drugs should be used by people with severe kidney disease.
PHOTO: Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk is seen on Oct. 16, 2024. (James Manning/PA Images via Getty Images)
Ad
related to: alendronate and bisphosphonate benefits weight loss scientific evidence